ESR1 and breast cancer: Moreover, tamoxifen (TAM), a selective estrogen receptor (ER) modulator that has been used for all stages of ER-positive breast cancers, is also associated with acquired resistance in breast cancer cells, after long-term treatment that initially responded to antiestrogen therapy [23].